MedTrace Logo

A Pilot Study of FFP104 in Subjects With Crohn's Disease

NCT02465944 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-08-24

No results posted yet for this study

Summary

This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease

Conditions

Interventions

DRUG

FFP104

Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)

DRUG

Placebo

Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)

Sponsors & Collaborators

  • Fast Forward Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-31
Completion
2017-12-31

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02465944 on ClinicalTrials.gov